A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Colon | Other Digestive Organ | Rectum
What is the purpose of this trial?
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).
- Trial withArcus Biosciences, Inc.
- Start Date02/06/2019
- End Date11/29/2020
- Last Updated01/20/2020
- Study HIC#2000024289